FDA medical oncologists discuss the accelerated approval of larotrectinib for adult and pediatric patients with solid tumors that have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion

FDA D.I.S.C.O.: FDA approval of larotrectinib for advanced malignancies with NTRK gene fusion

FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.) is an FDA podcast series that provides information about new product approvals, emerging safety information for cancer treatments, and other current topics in cancer drug development.

Science

Share FDA D.I.S.C.O.: FDA approval of larotrectinib for advanced malignancies with NTRK gene fusion

Sign up to save your podcasts

FDA D.I.S.C.O.: FDA approval of larotrectinib for advanced malignancies with NTRK gene fusion

FDA D.I.S.C.O.: FDA approval of larotrectinib for advanced malignancies with NTRK gene fusion